Bifogade filer
Q-linea signs first site for US study
Prenumeration
Beskrivning
| Land | Sverige |
|---|---|
| Lista | Small Cap Stockholm |
| Sektor | Hälsovård |
| Industri | Medicinteknik |
Q-linea AB (publ) (OMX: QLINEA) today announced that the company has contracted Thermo Fisher Scientific as the first site to participate in the company's US clinical study for ASTar®.
“This is very positive as it further strengthens our collaboration with Thermo Fisher Scientific. They have the reference method in susceptibility testing, which gives the study very good conditions, but it also opens up for further collaboration in the future,” said Jonas Jarvius, CEO of Q-linea.
Just as in Europe, the interest in testing ASTar has been great at several hospitals and Q-linea will select at least one more American site for the US clinical study. The study is expected to begin during the second quarter of 2021. Thermo Fisher Scientific will be the reference site for all samples in the study.
ASTar is a fully automatic and user-friendly system for antibiotic susceptibility testing (AST) with a short hands-on time and the capability to deliver a broad answer within approximately six hours for positive blood cultures.